Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

At the Fraunhofer Institute For Translational Medicine And Pharmacology ITMP in Berlin, clinical trials in immune system diseases focus strongly on chronic spontaneous urticaria and related forms of chronic inducible urticaria. These studies are designed to evaluate new therapies that may better control hives, itching, and flare activity for people living with persistent allergic and immune-driven skin symptoms.

• Testing new treatment options for chronic spontaneous urticaria
• Evaluating symptom relief in cold-induced urticaria and symptomatic dermographism
• Assessing the effectiveness of therapies aimed at reducing itch and hive activity

Several trials also look at longer-term disease control, helping researchers understand whether emerging treatments can maintain benefit over time and improve day-to-day quality of life.

Research in skin and connective tissue diseases at this site includes studies in more complex inflammatory conditions such as systemic sclerosis, rheumatoid arthritis, primary Sjögren’s disease, and idiopathic inflammatory myopathy. The main aim is to explore whether new immune-targeted approaches can improve disease control in people with severe, treatment-refractory illness.

• Studying difficult-to-treat systemic sclerosis and primary Sjögren’s disease
• Investigating therapies for rheumatoid arthritis and idiopathic inflammatory myopathy
• Evaluating immune-based treatments for immune-mediated inflammatory diseases

These trials are centered on safety and early signs of benefit, supporting the development of more precise options for patients with chronic inflammatory disease.

Another important area of research at the Fraunhofer Institute For Translational Medicine And Pharmacology ITMP is ANCA-associated vasculitis, a serious autoimmune disease that can affect blood vessels and multiple organs. The trials here are examining advanced immune therapies to see whether they can help patients whose disease remains active despite prior treatment.

• Exploring new approaches for ANCA-IgG-positive associated vasculitis
• Assessing safety and early effectiveness of bispecific T-cell engager therapies
• Supporting research for patients with treatment-refractory autoimmune disease

These studies aim to improve control of severe inflammation while offering a clearer picture of how innovative immune therapies may be used in challenging autoimmune conditions.